The impact of depth of response on long-term clinical outcomes: Exploratory analyses from multiple expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab in first-line recurrent/metastatic (R/M) HPV-negative head and neck carcinoma (HNSCC).

ficerafusp alfa (BCA101) - Bicara Therapeutics

Keytruda (pembrolizumab) - Merck (MSD)

https://www.asco.org/abstracts-presentations/263391

John Kaczmar; Ariel Birnbaum; Susannah Calhoun; Anurag Gupta; Jonathan Hayman; Zhao Yang; Jennifer Choe; Christine Chung; Glenn Hanna; Dan Zandberg; Tamara Sussman; Deborah Wong; Eric Sherman; Neal Akhave; Assuntina Sacco

Apr 21, 2026